A single infusion of one of two doses of SAR445088 — Sanofi’s potential successor to Enjaymo (sutimlimab-jome) —…
Articles by Marisa Wexler, MS
BioCryst is working to develop a new oral therapy for cold agglutinin disease (CAD) that suppresses the immune…
A bipartisan team of congressional representatives is proposing new legislation that aims to make it easier for people with rare…
In people with cold agglutinin disease (CAD), pre-treatment with rituximab and plasma exchange may help limit complications during surgeries…
In rare cases, cold agglutinin disease (CAD) may develop as a delayed complication of a combination of immune-activating cancer…
Daratumumab, which is approved to treat some cancers, was effective at controlling cold agglutinin disease (CAD) in an elderly…
A man had stroke-like symptoms, a heart attack, and rotting skin that were determined to be likely caused by…
A case of cold agglutinin disease (CAD), found to be secondary to a type of blood cancer called B-cell…
Specially designed miniaturized antibodies, or nanobodies, reduced blood cell destruction in a new mouse model of a disease similar to…
Long-term treatment with Enjaymo (sutimlimab-jome) in people with cold agglutinin disease (CAD) results in rapid and sustained reductions…